Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 5/20 | 0.61 |
| ▸ | GABBR1 | Q9UBS5 | 5/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.45 |
| ▸ | CTSA | P10619 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23750260 | 0.85 | NISCH (0.47) | GABBR2GABBR1LMNACYP2C9CYP3A4 | |
| SCHEMBL21632340 | 0.83 | GABBR2 (0.45) | GABBR2GABBR1LMNACYP2C9CYP3A4 | |
| SCHEMBL10497400 | 0.83 | CTSA (0.45) | GABBR2GABBR1CYP3A4CTSA | |
| SCHEMBL23750207 | 0.82 | NISCH (0.45) | GABBR2GABBR1LMNACYP2C9CYP3A4 | |
| SCHEMBL23750206 | 0.82 | NISCH (0.45) | GABBR2GABBR1LMNACYP2C9CYP3A4 | |
| Hydrochloric Acid SCHEMBL21956238 | 0.82 | GABBR2 (0.44) | GABBR2GABBR1LMNACYP2C9CYP3A4 | |
| SCHEMBL24878545 | 0.82 | NISCH (0.45) | GABBR2GABBR1LMNACYP2C9CYP3A4 | |
| SCHEMBL23750261 | 0.82 | NISCH (0.45) | GABBR2GABBR1LMNACYP2C9CYP3A4 | |
| SCHEMBL10507509 | 0.81 | NISCH (0.57) | LMNACYP2C9CYP3A4ADORA3NFKB1 | |
| SCHEMBL21631947 | 0.81 | CYSLTR2 (0.47) | GABBR2GABBR1LMNACYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011113904-A1 | MEDICAMENTS FOR THE PREVENTION AND TREATMENT OF A DISEASE ASSOCIATED WITH RETINAL GANGLION CELL DEGENERATION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2011-09-22 | — | — | WO | claimed |
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-05 | — | — | US | disclosed |
| US-20200031775-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-01-30 | — | — | US | disclosed |
| US-10385014-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | ARBOR PHARMACEUTICALS, LLC (US) | 2019-08-20 | — | — | US | disclosed |
| US-20180258032-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | ARBOR PHARMACEUTICALS, LLC | 2018-09-13 | — | — | US | disclosed |
| US-9944592-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170190657-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| EP-1660440-B1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT INC (US) | 2012-02-22 | — | — | EP | disclosed |
| US-20120016021-A1 | METHODS OF TREATING FRAGILE X SYNDROME, DOWN'S SYNDROME, AUTISM AND RELATED DISORDERS | XENOPORT, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2012009646-A1 | METHODS OF TREATING FRAGILE X SYNDROME, DOWN'S SYNDROME, AUTISM AND RELATED DISORDERS | XENOPORT, INC. (US) | 2012-01-19 | — | — | WO | disclosed |
| US-20040152775-A1 | Compounds useful in reflux disease | ASTRAZENECA AB (SE) | 2004-08-05 | — | — | US | disclosed |
| CN-1514825-A | Novel compounds useful in reflux disease | — | 2004-07-21 | — | — | CN | disclosed |
| EP-1399419-A1 | NEW COMPOUNDS USEFUL IN REFLUX DISEASE | AstraZeneca AB (SE) | 2004-03-24 | — | — | EP | disclosed |
| US-20030220303-A1 | New aminopropylphosphinic acids | ELEBRING THOMAS (SE) | 2003-11-27 | — | — | US | disclosed |
| US-6596711-B1 | GABA B receptor agonists for use in the treatment of CNS disorders, such as muscle relaxation in spinal spasticity, cardiovascular disorders, asthma, gut motility disorders such as irritable bowel syndrome and gastroesophogeal reflux | ASTRAZENECA AB (SE) | 2003-07-22 | — | — | US | disclosed |
| CN-1409716-A | New amino propylphosphinic acid | ASTRAZENECA AB (SE) | 2003-04-09 | — | — | CN | disclosed |
| WO-2002100823-A1 | NEW COMPOUNDS USEFUL IN REFLUX DISEASE | ASTRAZENECA AB (SE) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002100871-A1 | NEW COMPOUNDS USEFUL IN REFLUX DISEASE | ASTRAZENECA AB (SE) | 2002-12-19 | — | — | WO | disclosed |
| EP-1239843-A1 | NEW (AMINOPROPYL)METHYLPHOSPHINIC ACIDS | AstraZeneca AB (SE) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001041743-A1 | NEW (AMINOPROPYL)METHYLPHOSPHINIC ACIDS | ASTRAZENECA AB (SE) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220303-A1 | New aminopropylphosphinic acids | GABRP, GABRB1, GABRA1 | GABBR2 13/4885GABBR1 17/4885LMNA 4590/4885 |
| US-10385014-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | APEH, ABAT, SI | GABBR2 6/4885GABBR1 7/4885LMNA 3875/4885 |
| US-20180258032-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | APEH, ABAT, SI | GABBR2 6/4885GABBR1 7/4885LMNA 3875/4885 |
| US-20200031775-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | AADAC, NAT1, EPX | GABBR2 1861/4885GABBR1 1557/4885LMNA 694/4885 |
| US-20170190657-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | APEH, ABAT, SI | GABBR2 6/4885GABBR1 7/4885LMNA 3875/4885 |
| US-20040152775-A1 | Compounds useful in reflux disease | HRH2, HRH1, HRH4 | GABBR2 1721/4885GABBR1 1748/4885LMNA 4379/4885 |
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | AADAC, NAT1, EPX | GABBR2 1861/4885GABBR1 1557/4885LMNA 694/4885 |
| US-20120016021-A1 | METHODS OF TREATING FRAGILE X SYNDROME, DOWN'S SYNDROME, AUTISM AND RELATED DISORDERS | GABBR2, GABBR1, GABRB1 | GABBR2 1/4885GABBR1 2/4885LMNA 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.